Although the precise mechanisms of the contributions of SRSF2 mutations to the pathogenesis of MDS remain largely unknown, a growing number of studies have explained the mechanisms of SRSF2 mutations leading to the poor prognosis of MDS patients: (1) SRSF2 mutations occur early and are implicated as founder mutations in MDS[8,26], suggesting that they may play an important role in disease initiation. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.